These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 38758223)

  • 1. Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's.
    Song T; Wang Y; Silverglate BD; Grossberg GT
    Expert Opin Drug Metab Toxicol; 2024 Jun; 20(6):411-417. PubMed ID: 38758223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.
    Lowe SL; Duggan Evans C; Shcherbinin S; Cheng YJ; Willis BA; Gueorguieva I; Lo AC; Fleisher AS; Dage JL; Ardayfio P; Aguiar G; Ishibai M; Takaichi G; Chua L; Mullins G; Sims JR
    J Prev Alzheimers Dis; 2021; 8(4):414-424. PubMed ID: 34585215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer's disease.
    Shukla AK; Misra S
    J Basic Clin Physiol Pharmacol; 2024 Jan; 35(1-2):25-29. PubMed ID: 38053285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit.
    Høilund-Carlsen PF; Alavi A; Barrio JR; Castellani RJ; Costa T; Herrup K; Kepp KP; Neve RL; Perry G; Revheim ME; Robakis NK; Sensi SL; Vissel B
    Ageing Res Rev; 2024 Aug; 99():102348. PubMed ID: 38830549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
    Ross EL; Weinberg MS; Arnold SE
    JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease.
    Gueorguieva I; Willis BA; Chua L; Chow K; Ernest CS; Shcherbinin S; Ardayfio P; Mullins GR; Sims JR
    Clin Pharmacol Ther; 2023 Jun; 113(6):1258-1267. PubMed ID: 36805552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy, Tolerability, and Acceptability of Donanemab, Lecanemab, Aducanumab, Melatonin, and Aerobic Exercise for a Short Time on Cognitive Function in Mild Cognitive Impairment and Mild Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
    Terao I; Kodama W
    J Alzheimers Dis; 2024; 98(3):825-835. PubMed ID: 38461503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Still grasping at straws: donanemab in Alzheimer's disease.
    Doggrell SA
    Expert Opin Investig Drugs; 2021 Aug; 30(8):797-801. PubMed ID: 34162295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.
    Terao I; Kodama W
    Ageing Res Rev; 2024 Feb; 94():102203. PubMed ID: 38253184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease.
    Jin M; Noble JM
    eNeuro; 2024 Sep; 11(9):. PubMed ID: 39332901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling lecanemab as a treatment option for Alzheimer's disease.
    Schiller ER; Silverglate BD; Grossberg GT
    Expert Rev Neurother; 2024 May; 24(5):433-441. PubMed ID: 38566584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How donanemab data address the coverage with evidence development questions.
    Klein EG; Schroeder K; Wessels AM; Phipps A; Japha M; Schilling T; Zimmer JA
    Alzheimers Dement; 2024 Apr; 20(4):3127-3140. PubMed ID: 38323738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
    Qiao Y; Gu J; Yu M; Chi Y; Ma Y
    CNS Drugs; 2024 Mar; 38(3):169-192. PubMed ID: 38429615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donanemab in Early Alzheimer's Disease.
    Mintun MA; Lo AC; Duggan Evans C; Wessels AM; Ardayfio PA; Andersen SW; Shcherbinin S; Sparks J; Sims JR; Brys M; Apostolova LG; Salloway SP; Skovronsky DM
    N Engl J Med; 2021 May; 384(18):1691-1704. PubMed ID: 33720637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?
    Beveridge J; Kaniecki E; Naidu A; Silverglate BD; Grossberg G
    Expert Opin Emerg Drugs; 2024 Mar; 29(1):35-43. PubMed ID: 38193477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials.
    Rashad A; Rasool A; Shaheryar M; Sarfraz A; Sarfraz Z; Robles-Velasco K; Cherrez-Ojeda I
    Healthcare (Basel); 2022 Dec; 11(1):. PubMed ID: 36611492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer's disease.
    Lozupone M; Dibello V; Sardone R; Castellana F; Zupo R; Lampignano L; Bortone I; Stallone R; Altamura M; Bellomo A; Daniele A; Solfrizzi V; Panza F
    Expert Opin Drug Discov; 2024 Jun; 19(6):639-647. PubMed ID: 38685682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
    Shcherbinin S; Evans CD; Lu M; Andersen SW; Pontecorvo MJ; Willis BA; Gueorguieva I; Hauck PM; Brooks DA; Mintun MA; Sims JR
    JAMA Neurol; 2022 Oct; 79(10):1015-1024. PubMed ID: 36094645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-amyloid Antibody Drugs as Disease-Modifying Therapies for Alzheimer's Disease].
    Sato K; Iwatsubo T
    Brain Nerve; 2024 Sep; 76(9):991-995. PubMed ID: 39251217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling aducanumab as a treatment option for Alzheimer's disease: an overview of efficacy, safety and tolerability.
    Thussu S; Naidu A; Manivannan S; Grossberg GT
    Expert Rev Neurother; 2024 Nov; 24(11):1045-1053. PubMed ID: 39291991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.